drugset / Trial / NCT06085937

Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department

NCT06085937

Phase 1 Recruiting 50 enrolled Lindsay Maguire, MD
NaSingle-groupOpen-labelTreatment

Summary

There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.

Timeline

Start
2024-05-01
Primary completion
2026-04
Completion
2027-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.2 mg/kg Intravenous

Indications